IP Library Granted Patent US 9,803,201
Granted Patent B2
US 9,803,201 · App. 15/071,395 · Granted Oct 31, 2017

Disulfide-containing alkyne linking agents

Inventors: Aaron Almeida (Madison, WI); Andrei V. Blokhin (Fitchburg, WI); Darren H. Wakefield (Fitchburg, WI); Jonathan D. Benson (Stoughton, WI); David B. Rozema (Cross Plains, WI)
Assignee: Arrowhead Pharmaceuticals, Inc.
C12N15/113C12N15/111C12N2310/14C12N2310/315C12N2310/321C12N2310/322C12N2310/351C12N2310/3515C12N2320/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,803,201
App. No.
15/071,395
Granted
Oct 31, 2017
Kind
B2
Abstract

Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.

Claims (29)

1. A cyclooctyne-alkyl disulfide compound having the structure represented by:

wherein,

R 3 is C(R 5 R 6 ), wherein R 5 is hydrogen, methyl or ethyl, and R 6 is hydrogen, methyl or ethyl;

R 4 is C(R 7 R 8 ), wherein R 7 is hydrogen, methyl or ethyl, and R 8 is hydrogen, methyl or ethyl;

at least one of R 5 , R 6 , R 7 , and R 8 is methyl or ethyl;

L 1 is a first linker;

L 2 is a second linker; and

Y comprises a reactive group or a synthetic oligonucleotide.

2. The compound of claim 1 wherein R 5 or R 6 is methyl or ethyl and R 7 and R 8 are both hydrogen.

3. The compound of claim 1 wherein R 7 or R 8 is methyl or ethyl, and R 5 and R 6 are both hydrogen.

4. The compound of claim 1 wherein R 5 is CH 3 , and R 6 , R 7 and R 8 are each hydrogen.

5. The compound of claim 1 wherein R 7 is CH 3 , and R 5 , R 6 and R 8 are each hydrogen.

6. The compound of claim 1 wherein the synthetic oligonucleotide is an RNAi agent.

7. A cyclooctyne-alkyl disulfide compound having the structure represented by:

wherein,

R 3 is C(R 5 R 6 ), wherein R 5 is hydrogen, methyl or ethyl, and R 6 is hydrogen, methyl or ethyl;

R 4 is C(R 7 R 8 ), wherein R 7 is hydrogen, methyl or ethyl, and R 8 is hydrogen, methyl or ethyl;

at least one of R 5 , R 6 , R 7 , and R 8 is methyl or ethyl;

L 1 is a linker; and

Y comprises a reactive group or a synthetic oligonucleotide.

8. The compound of claim 7 wherein R 5 or R 6 is methyl or ethyl, and R 7 and R 8 are both hydrogen.

9. The compound of claim 7 wherein R 7 or R 8 is methyl or ethyl, and R 5 and R 6 are both hydrogen.

10. The compound of claim 7 wherein R 5 is CH 3 , and R 6 , R 7 and R 8 are each hydrogen.

11. The compound of claim 7 wherein R 7 is CH 3 , and R 5 , R 6 and R 8 are each hydrogen.

12. The compound of claim 7 wherein the synthetic oligonucleotide is an RNAi agent.

13. The compound of claim 1 where in the compound has the structure represented by:

wherein R comprises a reactive group, synthetic oligonucleotide, or RNAi agent.

14. The compound of claim 7 wherein the compound has the structure represented by:

wherein R is a reactive group, synthetic oligonucleotide, or RNAi agent.

Assignments (3)
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 039254/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2016
From: ALMEIDA, AARON; ROZEMA, DAVID B.; WAKEFIELD, DARREN H.; BLOKHIN, ANDREI; BENSON, JONATHAN D.
To: ARROWHEAD MADISON INC.
Reel/Frame 039012/0125 →
Continuity (4)
Provisional Application 62134186 · Mar 17, 2015
Provisional Application 62168244 · May 29, 2015
Provisional Application 62235860 · Oct 1, 2015
Related Publication 20160272971A1 · Sep 22, 2016